Quantcast

Latest Avanir Pharmaceuticals Inc. Stories

2014-09-16 08:38:12

PHOENIX, Sept. 16, 2014 /PRNewswire/ -- Today, Insiderslab.com revealed the latest insider trading research for Yahoo! (NASDAQ:YHOO), Apple (NASDAQ:AAPL), Facebook (NASDAQ:FB), Avanir Pharmaceuticals (NASDAQ:AVNR), Tesla Motors (NASDAQ:TSLA), and Twitter (NYSE:TWTR). US stock investors can access these reports through the links below, including stock performance, insider trading signals, and visual results. http://photos.prnewswire.com/prnvar/20100419/HKM001LOGO (Read full report...

2014-09-15 08:29:32

- Significantly Improved Agitation in 220-Patient 10-week Study - ALISO VIEJO, Calif., Sept. 15, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced positive results from its phase II clinical trial evaluating the safety and efficacy of AVP-923 for the treatment of agitation in patients with Alzheimer's disease. Treatment with AVP-923 was associated with significantly reduced agitation as measured by the primary endpoint, the agitation/aggression...

2014-09-02 08:31:21

ALISO VIEJO, Calif., Sept. 2, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that company management will present an overview of the company at the Morgan Stanley Global Healthcare Conference in New York. -- Presentation date: Tuesday September 9, 2014 -- Presentation time: 5:15 p.m. ET A live webcast and 30-day archive of this presentation will be available at http://ir.avanir.com. About Avanir Pharmaceuticals, Inc. Avanir Pharmaceuticals, Inc....

2014-08-26 08:31:43

--Study to Utilize Sequential Parallel Comparison Design to Minimize Placebo Response, Same Design Utilized in AVP-923 Phase II Study in Agitation in Alzheimer's Disease-- ALISO VIEJO, Calif., Aug. 26, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the enrollment of the first patient into a phase II study to evaluate the efficacy, safety and tolerability of AVP-786 for the adjunctive treatment of major depressive disorder (MDD). AVP-786 is a novel...

2014-08-05 16:27:40

ALISO VIEJO, Calif., Aug. 5, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today reported financial results for the three and nine months ended June 30, 2014. Quarterly Financial Highlights -- Total company net revenues of $28.6 million. -- Net NUEDEXTA® sales of $26.5 million. -- Cash, cash equivalents, and restricted investments of $87.6 million as of June 30, 2014. "We had a great quarter across all aspects of our business. I am delighted with...

2014-08-05 08:34:52

ALISO VIEJO, Calif., Aug. 5, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that company management will present an overview of the company at the following conferences in August. -- Wedbush Life Sciences Conference -- Presentation date: Tuesday August 12, 2014 -- Presentation time: 9:45 a.m. ET -- Canaccord Genuity Annual Growth Conference -- Presentation date: Wednesday, August 13, 2014 -- Presentation time:...

2014-07-16 08:29:14

--Interim Results Show NUEDEXTA Provides Meaningful Reduction of PBA Episodes and is Generally Well Tolerated in Alzheimer's Disease/Dementia Population-- ALISO VIEJO, Calif., July 16, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced interim data from the phase IV PRISM II study showing that treatment with NUEDEXTA(®) substantially reduced symptoms of pseudobulbar affect (PBA) in patients with Alzheimer's disease/dementia. PBA is a distressing neurologic...

2014-06-30 20:22:37

ALISO VIEJO, Calif., June 30, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that data related to pseudobulbar affect (PBA), a neurological condition characterized by disruptive, uncontrollable episodes of laughing or crying, and NUEDEXTA® (dextromethorphan hydrobromide/quinidine sulfate), the only FDA-approved product for the treatment of PBA, will be presented at the Alzheimer's Association International Conference (AAIC), being held at the Bela...

2014-06-24 08:31:20

ALISO VIEJO, Calif., June 24, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that data related to the safety and efficacy of AVP-825, a Breath-Powered(TM) Nasal Delivery of Powdered Sumatriptan for the acute treatment of migraine, will be presented at the American Headache Society's 56(th) Annual Scientific Meeting. AVP-825 is an investigational drug-device combination product consisting of low-dose sumatriptan powder delivered intranasally utilizing a novel...

2014-06-10 04:22:17

--Migraine Sufferers Achieved Greater Rates of Pain Relief and Pain Freedom Within 30 Minutes with AVP-825 Treatment Compared with Oral Sumatriptan Treatment-- ALISO VIEJO, Calif., June 10, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that COMPASS, its Phase IIIb clinical trial comparing the efficacy and safety of the investigational product AVP-825 22mg to sumatriptan 100mg tablets for the treatment of acute migraines in adults, met the primary...


Word of the Day
tessitura
  • The prevailing range of a vocal or instrumental part, within which most of the tones lie.
This word is Italian in origin and comes from the Latin 'textura,' web, structure.